Drug Profile
Olodanrigan - Novartis
Alternative Names: EMA-401Latest Information Update: 15 May 2020
Price :
$50
*
At a glance
- Originator Spinifex Pharmaceuticals
- Developer Novartis
- Class Analgesics; Small molecules; Tetrahydroisoquinolines
- Mechanism of Action Angiotensin type 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
Most Recent Events
- 10 Apr 2019 Novartis terminates the phase-II EMPHENE trial in Post-herpetic Neuralgia (Treatment-experienced) in Australia, Austrial, Belgium, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, South Korea, Norway, Poland, Portugal, Slovakia, Taiwan, United Kingdom, Spain (PO) (NCT03094195)
- 28 Mar 2018 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in Australia (PO, Tablet)
- 28 Mar 2018 No recent reports of development identified for phase-I development in Postherpetic-neuralgia(In volunteers) in Australia (PO, Tablet)